Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Tonia Vincent writes in Osteoarthritis and Cartilage about the importance of making negative data more accessible in osteoarthritis research.

Generating a piece of data that supports a new idea or hypothesis is a satisfying moment in scientific research. These data often result in scientific publications that stimulate new directions in the field. Negative data also hold value as researchers refine or revise their original hypothesis. But these results are more likely to be stored away in a lab notebook than written up for publication.

In an invited editorial published in Osteoarthritis and Cartilage, Professor Tonia Vincent argues that negative in vivo studies are crucial for understanding the causes of osteoarthritis (OA), and urges more effort to make these data publicly available.

Tonia wrote the piece as part of a Themed Issue on Negative in Vivo Studies that she co-edited together with Professor Anne-Marie Malfait, Rush University Medical Centre. The authors describe how negative studies can help rule out potential targets in OA. This was the case for Adamst4 – an enzyme that degrades cartilage in a dish but is dispensable for tissue destruction in joints.

The editorial also considers how researchers can make their negative data more accessible. Suggestions range from greater inclusion of negative data in supplemental manuscript figures, to the creation of an online repository where negative data can be deposited alongside detailed methodology. Importantly this could limit duplication between laboratories and help reduce the use of animals in research.

The Themed issue contains seven manuscripts reporting negative data that the editors felt have the potential to steer future OA research. These papers are complemented by expert reviews outlining how to design and report studies of OA disease models so that negative results can be interpreted more easily.

Tonia hopes this issue will stimulate the OA community to think differently about the value of negative results and ensure these data are shared more widely.

Similar stories

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

A drug being trialled to treat cancer, could be the key to reducing gut inflammation

Published in Nature Communications, a new study reveals a new signalling pathway behind macrophage inflammatory activity

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Exploring the link between joint injury and osteoarthritis

A new study published in The Lancet Rheumatology shows potential ways to predict how likely someone is to develop osteoarthritis after a knee injury.

Vaccine developed to treat osteoarthritic pain

Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.